A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Trial Profile

A China Phase I, Open Label, Multi-Center, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, and Antitumor Activities of BGB-290 in Subjects With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs BGB 290 (Primary)
  • Indications Cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors BeiGene
  • Most Recent Events

    • 21 Dec 2016 According to a BeiGene Ltd. media release, Professor Binghe Xu from The Chinese Academy of Medical Sciences Cancer Hospital is the principal investigator of the study.
    • 21 Dec 2016 According to a BeiGene Ltd. media release, the first patient has been dosed in this trial.
    • 21 Dec 2016 According to a BeiGene Ltd. media release, status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top